RT Journal Article
T1 miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma.
A1 Fuertes, Teresa
A1 Ramiro, Almudena R
A1 Yébenes, 
A1 García-Yébenes Mena, Virginia Pilar
AB Non-Hodgkin lymphoma (NHL) is a diverse class of hematological cancers, many of which arise from germinal center (GC)-experienced B cells. Thus GCs, the sites of antibody affinity maturation triggered during immune responses, also provide an environment that facilitates B cell oncogenic transformation. miRNAs provide attractive and mechanistically different strategies to treat these malignancies based on their potential for simultaneous modulation of multiple targets. Here, we discuss the scientific rationale for miRNA-based therapeutics in B cell neoplasias and review recent advances that may help establish a basis for novel candidate miRNA-based therapies for B cell-NHL (B-NHL)
PB Cell Press
SN 1471-4981
YR 2020
FD 2020-10-03
LK https://hdl.handle.net/20.500.14352/91808
UL https://hdl.handle.net/20.500.14352/91808
LA eng
NO Fuertes T, Ramiro AR, de Yebenes VG. miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma. Trends Immunol. 2020 Oct;41(10):932-947. doi: 10.1016/j.it.2020.08.006. Epub 2020 Sep 1. PMID: 32888820
NO Ministerio de Ciencia e Innovación
NO Ministerio de Ciencia, Innovacion y Universidades
DS Docta Complutense
RD 11 abr 2025